SEC Tracker
Get the app
PTGX · XBRL financial data

Protagonist Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (PTGX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers———————5,546———213,475
Research and development30,66428,899*33,73433,52035,97034,904*35,89337,03640,00346,358*46,73942,061
General and administrative7,6628,052*14,9109,44010,1588,954*11,73810,55111,13011,434*13,27712,648
Total operating expenses38,32636,951*48,64442,96046,12843,858*47,63147,58751,13357,792*60,01654,709
Operating income (loss)(38,326)23,049*206,309(38,793)(41,453)126,780*(19,310)(42,041)(46,421)(50,355)*(3,648)158,766
Interest income4,2524,242*4,3767,4047,6826,853*7,5737,4067,0496,761*5,8766,429
Other income (expense)(31)44*(19)9714131*823633(124)*53(81)
Income tax expense (benefit)00*3,326(676)(420)1,990*01720666*(1,502)2,265
Net income (loss)(34,105)27,335*207,340(30,616)(33,210)131,674*(11,655)(34,771)(39,339)(44,384)*3,783162,849
Earnings per share, basic USD per share(0.58)—3.41(0.50)(0.54)2.11*(0.19)(0.55)(0.62)(0.69)*0.062.47
Earnings per share, diluted USD per share(0.58)—3.26(0.50)(0.54)—(0.19)(0.55)(0.62)(0.69)*0.052.29
Weighted average shares, basic thousands of shares59,18360,388*60,85661,30561,76862,328*62,96463,51163,77264,032*65,08865,936
Weighted average shares, diluted thousands of shares59,18360,388*63,59561,30561,76873,585*62,96463,51163,77264,032*70,49371,007

Balance sheet

CSV

Fiscal quarters (PTGX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents230,527186,727172,568355,643131,12197,249139,653168,543113,713128,390193,712420,078
Marketable securities90,224154,890150,067208,354337,600321,664434,707401,922462,404438,974354,074362,498
Marketable securities, non-current1,985——31,447114,560140,252123,517102,493102,70378,63872,54866,875
Prepaid and other current assets4,1303,9604,8756,8858,0487,7288,6758,6989,72410,08912,0067,790
Total current assets324,881355,577627,553570,925476,769591,641605,860602,526586,424577,574613,455807,148
Property and equipment, net1,4211,1951,1111,7802,4683,1903,5304,1084,1003,8603,7783,456
Right-of-use asset1,50495438710,2529,8359,4179,0008,5898,1747,8297,3906,946
Total assets330,016357,951629,276614,629603,857744,725742,132718,006701,688668,188697,459885,544
Accounts payable1,2527723,5073,6293,0491,6152,9173,2495,6465,3398,4373,459
Accrued liabilities24,80919,35816,48715,17520,73923,69311,84315,39722,86828,26917,49121,667
Total current liabilities27,86721,27439,91041,57844,57847,39835,11235,50744,94245,44134,54937,181
Lease liability, non-current———10,97110,85510,3569,7929,1068,5218,0407,4376,820
Total liabilities27,86721,27468,83273,30571,94269,43053,08049,98856,25153,48141,98644,001
Accumulated deficit(643,045)(615,710)(408,370)(438,986)(472,196)(340,522)(352,177)(386,948)(426,287)(470,671)(466,888)(304,039)
Total stockholders' equity302,149336,677560,444541,324531,915675,295689,052668,018645,437614,707655,473841,543
Total liabilities and equity330,016357,951629,276614,629603,857744,725742,132718,006701,688668,188697,459885,544
Common shares outstanding (cover page) thousands of shares57,67858,27558,65258,90559,59861,38461,98262,21162,51663,80964,31164,708

Cash flows

CSV

Fiscal quarters (PTGX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(34,105)27,335*207,340(30,616)(33,210)131,674*(11,655)(34,771)(39,339)(44,384)*3,783162,849
Stock-based compensation6,765*6,601*9,3528,944*10,165*9,093*13,80210,912*10,559*10,701*14,51914,037*
Depreciation and amortization244*248*236241*231*118*239304*361*376*407397*
Net cash from operating activities(26,611)*16,960*(27,429)268,622*(27,863)*(29,178)*125,363(28,780)*(1,937)*(36,975)*(48,943)219,052*
Purchases of property and equipment404*19*24228*775*310*545813*88*144*215168*
Net cash from investing activities(13,559)*(61,287)*6,071(88,119)*(208,710)*(8,725)*(94,402)54,810*(58,555)*48,815*90,892(2,430)*
Proceeds from issuing common stock(78)*8*——————————
Net cash from financing activities35,315*527*7,1992,572*12,051*4,031*11,4432,925*5,659*2,837*23,3749,743*
Net change in cash(4,855)*(43,800)*(14,159)183,075*(224,522)*(33,872)*42,40428,955*(54,833)*14,677*65,323226,365*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Protagonist Therapeutics420,078213,475219,052*64.7M— 10-QJun 30, 2026
Prestige Consumer Healthcare89,127265,71070,78847.4M— 10-QJun 30, 2026
Viking Therapeutics677,6090(138,194)*127.5M7.6 quarters 10-QSep 30, 2026
Catalyst Pharmaceuticals755,859149,39059,587122.4M— 10-QMar 31, 2026
Cytokinetics255,27128,624(159,840)*139.0M7.3 quarters 10-QJun 30, 2026
TG Therapeutics482,575240,33539,263*153.1M— 10-QJun 30, 2026
Summit Therapeutics419,365not reported(141,124)*797.7M4.9 quarters 10-QJun 30, 2026
Ultragenyx Pharmaceutical125,000214,000(97,000)*98.6M3.0 quarters 10-QJun 30, 2026
Avidity Biosciences382,517860*(169,773)*155.1M2.3 quarters 10-KDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.